JP4166275B2 - グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体 - Google Patents

グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体 Download PDF

Info

Publication number
JP4166275B2
JP4166275B2 JP52003397A JP52003397A JP4166275B2 JP 4166275 B2 JP4166275 B2 JP 4166275B2 JP 52003397 A JP52003397 A JP 52003397A JP 52003397 A JP52003397 A JP 52003397A JP 4166275 B2 JP4166275 B2 JP 4166275B2
Authority
JP
Japan
Prior art keywords
heparin
glycosaminoglycan
conjugate
ath
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP52003397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000501082A (ja
JP2000501082A5 (enExample
Inventor
レスリー ベリー，
モウリーン アンドリュー，
Original Assignee
ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド filed Critical ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド
Publication of JP2000501082A publication Critical patent/JP2000501082A/ja
Publication of JP2000501082A5 publication Critical patent/JP2000501082A5/ja
Application granted granted Critical
Publication of JP4166275B2 publication Critical patent/JP4166275B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP52003397A 1995-11-30 1996-11-29 グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体 Expired - Fee Related JP4166275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/564,976 1995-11-30
US08/564,976 US6562781B1 (en) 1995-11-30 1995-11-30 Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
PCT/CA1996/000799 WO1997019701A2 (en) 1995-11-30 1996-11-29 Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates

Publications (3)

Publication Number Publication Date
JP2000501082A JP2000501082A (ja) 2000-02-02
JP2000501082A5 JP2000501082A5 (enExample) 2004-10-21
JP4166275B2 true JP4166275B2 (ja) 2008-10-15

Family

ID=24256690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52003397A Expired - Fee Related JP4166275B2 (ja) 1995-11-30 1996-11-29 グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体

Country Status (8)

Country Link
US (2) US6562781B1 (enExample)
EP (1) EP0863768B1 (enExample)
JP (1) JP4166275B2 (enExample)
AT (1) ATE350066T1 (enExample)
AU (1) AU7688396A (enExample)
CA (1) CA2237159C (enExample)
DE (1) DE69636813T2 (enExample)
WO (1) WO1997019701A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405905B (de) * 1997-03-25 1999-12-27 Immuno Ag Neue verwendung von antithrombin iii
FI974321A0 (fi) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
WO2000001406A1 (fr) * 1998-07-07 2000-01-13 Welfide Corporation Utilisation medicinale du cofacteur ii de l'heparine
WO2001005434A2 (en) * 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
AU2003233428B2 (en) * 2002-04-01 2008-07-31 The University Of Texas Medical Branch Treatment of lung disorder
CA2556785A1 (en) * 2003-02-20 2004-09-02 Hamilton Civic Hospitals Research Development Inc. Coating composition for polymeric surfaces comprising serpin or serpin derivatives
EP1663299A4 (en) * 2003-08-12 2009-09-16 Hamilton Civic Hospitals Res METHODS FOR PREVENTING NEUROLOGICAL ACCIDENTS
US7146034B2 (en) * 2003-12-09 2006-12-05 Superpower, Inc. Tape manufacturing system
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
ATE538814T1 (de) 2005-01-06 2012-01-15 Discovery Lab Inc Dosierungsschema unter verwendung eines tensids zur behandlung oder verhinderung von lungendysplasien
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US11229746B2 (en) 2006-06-22 2022-01-25 Excelsior Medical Corporation Antiseptic cap
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma HEPAROSANPOLYMERS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE THEREOF FOR THE REINFORCEMENT OF THERAPEUTICS
US9078992B2 (en) 2008-10-27 2015-07-14 Pursuit Vascular, Inc. Medical device for applying antimicrobial to proximal end of catheter
US9849276B2 (en) 2011-07-12 2017-12-26 Pursuit Vascular, Inc. Method of delivering antimicrobial to a catheter
US10166381B2 (en) 2011-05-23 2019-01-01 Excelsior Medical Corporation Antiseptic cap
EP3020417A4 (en) * 2013-07-10 2017-01-18 Seikagaku Corporation Pharmaceutical composition for respiratory administration
JP6478115B2 (ja) 2013-09-30 2019-03-06 生化学工業株式会社 タンパク質の血中滞留性の増強方法
EP3137122B1 (en) 2014-05-02 2019-09-04 Excelsior Medical Corporation Strip package for antiseptic cap
GB201415062D0 (en) 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
SG11201702160TA (en) * 2014-09-18 2017-04-27 Chondronest Sa Composition containing glycosaminoglycans and proteins
EP3757136B1 (en) * 2015-01-09 2023-07-19 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases
WO2016182822A1 (en) 2015-05-08 2016-11-17 Icu Medical, Inc. Medical connectors configured to receive emitters of therapeutic agents
WO2018071717A1 (en) 2016-10-14 2018-04-19 Icu Medical, Inc. Sanitizing caps for medical connectors
WO2018204206A2 (en) 2017-05-01 2018-11-08 Icu Medical, Inc. Medical fluid connectors and methods for providing additives in medical fluid lines
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
AU2019384564B2 (en) 2018-11-21 2023-11-23 Icu Medical, Inc. Antimicrobial device comprising a cap with ring and insert
AU2021396147A1 (en) 2020-12-07 2023-06-29 Icu Medical, Inc. Peritoneal dialysis caps, systems and methods

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824092A (en) 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
US3616935A (en) 1970-02-05 1971-11-02 Dow Chemical Co Preparation of antithrombogenic surfaces
US3673612A (en) 1970-08-28 1972-07-04 Massachusetts Inst Technology Non-thrombogenic materials and methods for their preparation
SE392038B (sv) 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
JPS6040859B2 (ja) 1977-07-27 1985-09-12 喜温 三浦 抗血栓性人工医療材料
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
FR2472390A1 (fr) 1979-05-04 1981-07-03 Merieux Inst Procede de preparation de concentres de complexe prothrombinique hautement purifies, et concentres obtenus
CA1171375A (en) 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity
US4446126A (en) 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Antithrombin-heparin complex and method for its production
US4604762A (en) 1981-02-13 1986-08-12 Thoratec Laboratories Corporation Arterial graft prosthesis
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
NL188622C (nl) * 1981-12-15 1992-08-17 Cordis Europ Werkwijze ter verbetering van de bloedcompatibiliteit van een materiaaloppervlak door bekleding daarvan met een heparine of heparine-analoga en een eiwit houdende film, alsmede voorwerp, omvattende een oppervlak met verbeterde bloedcompatibiliteit verkregen onder toepassing van een op het oppervlak aangebrachte heparine of heparine-analoga en een eiwit houdende film.
SE8200751L (sv) 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
EP0098814B1 (en) 1982-06-10 1986-10-15 KabiVitrum AB Antithrombin-heparin complex
US5002582A (en) 1982-09-29 1991-03-26 Bio-Metric Systems, Inc. Preparation of polymeric surfaces via covalently attaching polymers
AT379310B (de) 1983-05-20 1985-12-27 Immuno Ag Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates
DE3331009A1 (de) 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4448718A (en) * 1983-09-13 1984-05-15 Massachusetts Institute Of Technology Method for the preparation of collagen-glycosaminoglycan composite materials
US4689323A (en) 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
DE3422494A1 (de) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Verfahren und vorrichtung zur spezifischen adsorption von heparin
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
CH665954A5 (fr) 1985-07-08 1988-06-30 Battelle Memorial Institute Substrat dont la surface presente une activite antithrombogenique.
US4745180A (en) 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
DE3636590A1 (de) 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
DE3639561A1 (de) 1986-11-20 1988-06-01 Baumann Hanno Verfahren zur herstellung von nicht-thrombogenen substraten
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
NL8701337A (nl) 1987-06-09 1989-01-02 Sentron V O F Substraat voorzien van een bloedcompatibel oppervlak, verkregen door koppeling aan het oppervlak van een fysiologisch aktieve stof met remmende invloed op de vorming van bloedstolsels en/of in staat om gevormde bloedstolsels af te breken, alsmede werkwijze ter vervaardiging van het substraat.
JP2739050B2 (ja) 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
DE3806562A1 (de) 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff
FR2631970B1 (fr) 1988-05-24 1993-12-24 Sanofi N-polyosyl-polypeptides
DE3819079A1 (de) 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
US5262451A (en) 1988-06-08 1993-11-16 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5182317A (en) 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5338770A (en) 1988-06-08 1994-08-16 Cardiopulmonics, Inc. Gas permeable thrombo-resistant coatings and methods of manufacture
CA1336396C (en) 1988-07-25 1995-07-25 Kiyoshi Kita Intraocular anticoagulant including antithrombin iii and method of administration
FR2635019B1 (fr) 1988-08-02 1992-06-12 Centre Nat Rech Scient Materiau capable de fixer les substances biologiques, et ses applications notamment comme support de chromatographie d'affinite
US5023078A (en) * 1988-08-10 1991-06-11 Albert P. Halluin Plasminogen activator-heparin conjugates
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
US5270046A (en) 1988-09-27 1993-12-14 Ube Industries, Ltd. Heparin bound anti-thrombotic material
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
NL194941C (nl) 1990-02-15 2003-08-04 Cordis Corp Werkwijze voor het aanbrengen van een fysiologisch actieve verbinding op een substraatoppervlak.
US5275838A (en) 1990-02-28 1994-01-04 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
JP2975632B2 (ja) 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5222971A (en) 1990-10-09 1993-06-29 Scimed Life Systems, Inc. Temporary stent and methods for use and manufacture
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5159050A (en) 1991-05-09 1992-10-27 Becton, Dickinson And Company Polyurethane and medical article therefrom
AT395596B (de) 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
SG81873A1 (en) 1991-08-16 2001-07-24 Miles A Galin Medicament coated refractive anterior chamber ocular implant
SE470006B (sv) 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
AU649885B2 (en) 1991-10-01 1994-06-02 Nisshinbo Industries, Inc. Antithrombotic resin, tube, film and coating
US5319072A (en) 1992-01-10 1994-06-07 Alpha Therapeutic Corporation Human antithrombin-III preparation
US5436291A (en) 1992-07-09 1995-07-25 University Of Michigan, The Board Of . . . Calcification-resistant synthetic biomaterials
CA2154166A1 (en) 1992-11-19 1994-05-26 Roger E. Marchant Nonthrombogenic implant surfaces
KR100330540B1 (ko) 1993-04-05 2002-09-04 웰파이드 코포레이션 안티트롬빈-iii액상제제및그안정화방법
JPH09501719A (ja) * 1993-08-19 1997-02-18 ミネソタ マイニング アンド マニュファクチャリング カンパニー ヘパリン官能アフィニティー支持体
IL110367A (en) 1994-07-19 2007-05-15 Colbar Lifescience Ltd Collagen-based matrix
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5876433A (en) 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5811151A (en) 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US5855618A (en) 1996-09-13 1999-01-05 Meadox Medicals, Inc. Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin
US5851229A (en) 1996-09-13 1998-12-22 Meadox Medicals, Inc. Bioresorbable sealants for porous vascular grafts
US5741881A (en) 1996-11-25 1998-04-21 Meadox Medicals, Inc. Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US5891196A (en) 1997-04-16 1999-04-06 Baxter International Inc. Method for actively binding heparin to crosslinked biological tissues
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US20010007063A1 (en) 1997-06-18 2001-07-05 Yoshihiro Oyama Antithrombotic medical material
US5945457A (en) 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US6024918A (en) 1998-03-13 2000-02-15 Medtronic, Inc. Method for attachment of biomolecules to surfaces of medical devices
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device

Also Published As

Publication number Publication date
US6562781B1 (en) 2003-05-13
AU7688396A (en) 1997-06-19
ATE350066T1 (de) 2007-01-15
JP2000501082A (ja) 2000-02-02
EP0863768A2 (en) 1998-09-16
EP0863768B1 (en) 2007-01-03
US20030100487A1 (en) 2003-05-29
WO1997019701A3 (en) 1997-08-28
DE69636813D1 (de) 2007-02-15
WO1997019701A2 (en) 1997-06-05
CA2237159A1 (en) 1997-06-05
DE69636813T2 (de) 2007-10-04
CA2237159C (en) 2010-11-16

Similar Documents

Publication Publication Date Title
JP4166275B2 (ja) グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体
US6491965B1 (en) Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) Methods of coating a device using anti-thrombin heparin
US20190030066A1 (en) Antithrombin-heparin compositions and methods
US5280016A (en) Non-anticoagulant heparin derivatives
DK173982B1 (da) Depolymeriserede heparinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat samt biologisk reagens med indhold heraf
US4810784A (en) Process for covalent coupling for the production of conjugates, and products hereby obtained
US5250519A (en) Non-anticoagulant heparin derivatives
ES2242980T3 (es) Dermatan disulfato, un inhibidor de la generacion de trombina y de la activacion del complemento.
ES2341249T3 (es) Derivados polisacaridos con alta actividad antitrombotica en plasma.
EP0137356B1 (en) Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
WO1992002232A1 (en) Heparin fragment showing complement inhibition activity
Berry et al. Antithrombin–heparin complexes
US4623718A (en) Novel composition of matter of antithrombin III bound to a heparin fragment
AU2016274868B2 (en) Medical devices, systems, and methods utilizing antithrombin-heparin compositions
WO1994008595A1 (en) Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
Mattsson et al. Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III.
CA2378225A1 (en) Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
JPH02238879A (ja) Ｎ―ポリオシル―ポリペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070918

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080701

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080730

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110808

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110808

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110808

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110808

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120808

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130808

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees